All Hong Kong stocks quotes are at least 15 minutes delayed.
01276
HENGRUI PHARMA
HKD
68.450-1.500
(-2.14%)
1D
AI Analysis
High
71.750
Open
70.200
VWAP
69.00
Vol
6.00M
Mkt Cap
484.00B
Low
68.450
Amount
435.00M
EV/EBITDA(TTM)
39.00
Total Shares
7.00B
EV
351.00B
EV/OCF(TTM)
40.00
P/S(TTM)
12.00
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
Show More
News
Money Flow
Over the past 66 trading days, overall net money flow is 12.00M, with retail investors contributing 10.00M and major investors adding -3.00M.
Net Buy $ Volume
Net Sell $ Volume
Valuation Metrics
Forward PE

5Y Average PE
52.56
Current PE
44.94
Overvalued PE
61.90
Undervalued PE
43.21
Forward EV/EBITDA

5Y Average EV/EBITDA
42.21
Current EV/EBITDA
32.95
Overvalued EV/EBITDA
50.53
Undervalued EV/EBITDA
33.90
Forward PS

5Y Average PS
11.22
Current PS
11.02
Overvalued PS
13.03
Undervalued PS
9.40
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly

No data
Short Selling
People Also Watch




